2,2-dimethylbutyric acid has been researched along with Anemia, Sickle Cell in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abboud, MR; Ataga, KI; Buchanan, GR; El-Beshlawy, A; Ghalie, RG; Inati, A; Kutlar, A; Perrine, SP; Reid, ME; Smith, H; Taher, AT | 1 |
| Abboud, MR; El Beshlawy, A; Ghalie, RG; Haynes, J; Inati, A; Kutlar, A; Manwani, D; Reid, ME; Sharon, B; Smith, W; Taher, AT; Ward, R | 1 |
| Cohen, H; Ghalie, R; Knapp, E; Kutlar, A; Manwani, D | 1 |
| Ataga, K; Berenson, R; Blair-Britt, L; Glass, J; Keefer, JR; Kutlar, A; Labotka, R; Neumayr, L; Perrine, SP; Reid, M; Vichinsky, EP; Wargin, WA | 1 |
3 trial(s) available for 2,2-dimethylbutyric acid and Anemia, Sickle Cell
| Article | Year |
|---|---|
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Butyrates; Child; Cohort Studies; Dose-Response Relationship, Drug; Female; Fetal Hemoglobin; Gastritis; Hematinics; Heterozygote; Humans; Hydroxyurea; Incidence; Male; Middle Aged; Patient Dropouts; Promoter Regions, Genetic; Sickle Cell Trait; Up-Regulation; Young Adult | 2013 |
A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Butyrates; Child; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fetal Hemoglobin; Humans; Male; Middle Aged; Placebos; Young Adult | 2014 |
A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Biological Availability; Butyrates; Chromatography, High Pressure Liquid; Cohort Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Erythrocytes; Female; Fetal Hemoglobin; Hematinics; Humans; Male; Middle Aged; Young Adult | 2012 |
1 other study(ies) available for 2,2-dimethylbutyric acid and Anemia, Sickle Cell
| Article | Year |
|---|---|
Intrapatient variability in fetal hemoglobin measurements over time in sickle cell patients not on fetal hemoglobin inducing agents.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Butyrates; Child; Clinical Trials, Phase II as Topic; Data Interpretation, Statistical; Fetal Hemoglobin; Humans; Middle Aged; Time Factors; Young Adult | 2016 |